Literature DB >> 19007795

Mathematical model for G-CSF administration after chemotherapy.

Catherine Foley1, Michael C Mackey.   

Abstract

Granulocyte-colony stimulating factor (G-CSF) is used clinically for treating chemotherapy-induced neutropenia (low neutrophil levels). Here we present a delay differential equation model for the regulation of neutrophil production that accounts for the effects of G-CSF. Using a combination of analysis and numerical simulations, we use this model to study the effects of delaying G-CSF treatment following chemotherapy for two recombinant forms of G-CSF (filgrastim and pegfilgrastim). We also examine the consequences of varying the duration of filgrastim treatment. We found that varying the starting day or the duration of G-CSF treatment can lead to different qualitative responses in the neutrophil count. These changes can be explained by the coexistence of two stable solutions in the mathematical model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007795     DOI: 10.1016/j.jtbi.2008.09.043

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  15 in total

1.  Closed form solutions and dominant elimination pathways of simultaneous first-order and Michaelis-Menten kinetics.

Authors:  Xiaotian Wu; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-13       Impact factor: 2.745

2.  Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-09       Impact factor: 2.745

3.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

4.  Understanding, treating and avoiding hematological disease: better medicine through mathematics?

Authors:  David C Dale; Michael C Mackey
Journal:  Bull Math Biol       Date:  2014-09-12       Impact factor: 1.758

Review 5.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

6.  Transit and lifespan in neutrophil production: implications for drug intervention.

Authors:  Daniel Câmara De Souza; Morgan Craig; Tyler Cassidy; Jun Li; Fahima Nekka; Jacques Bélair; Antony R Humphries
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-13       Impact factor: 2.745

7.  A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.

Authors:  M Scholz; M Ackermann; C Engel; F Emmrich; M Loeffler; M Kamprad
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

8.  Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Authors:  O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

9.  Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia.

Authors:  Călin Căinap; Sânziana Cetean-Gheorghe; Laura Ancuta Pop; Daniel Corneliu Leucuta; Doina Piciu; Andra Mester; Cătălin Vlad; Crişan Ovidiu; Alexandra Gherman; Cristina Crişan; Alina Bereanu; Ovidiu Bălăcescu; Anne Marie Constantin; Irina Dicu; Loredana Bălăcescu; Adina Stan; Patriciu Achimaş-Cadariu; Simona Căinap
Journal:  Medicina (Kaunas)       Date:  2021-06-30       Impact factor: 2.430

10.  Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.

Authors:  Markus Scholz; Sibylle Schirm; Marcus Wetzler; Christoph Engel; Markus Loeffler
Journal:  Theor Biol Med Model       Date:  2012-07-30       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.